DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma
Belantamab mafodotin induced deep and durable responses in relapsed refractory myeloma patients
What is the DREAMM-5 platform trial?
The DREAMM-5 platform trials studies the single-agent belantamab mafodotin (GSK2857916), a B-cell maturation antigen targeting immunoconjugates.
In this video:
Dr. Paul G. Richardson (Dana Farber Cancer Institute — Boston) explains that belantamab mafodotin induced deep and durable responses in patients with relapsed refractory multiple myeloma with a manageable safety profile. He describes how this platform trial design allowed for efficient evaluation of belantamab mafodotin in combination with other anti-myeloma agents, such as a humanized wild-type IgG1 anti-OX40 agonist, an IgG4 inducible T-cell costimulatory (ICOS) agonist, and a gamma-secretase inhibitor.
The unique, multimodal mechanisms of action (MoAs) of belantamab mafodotin, in combination with MoAs of these agents, has the potential to achieve synergistic effects in MM, to further enhance anti-myeloma activity without compromising safety.
Clinical trial information: NCT04162210
PAUL G. RICHARDSON, MD
Paul G. Richardson, M.D. is the Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston. He is also an Institute Physician and a RJ Corman Professor of Medicine, at Harvard Medical School in Cambridge, MA. In addition to multiple myeloma, his key clinical interests are regimen-related toxicity, stem cell transplantation, experimental therapies and cancer pharmacology, and more. Visit Dr. Paul Richardson’s full biography.